Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
5000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2006-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
* To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Eligibility:
-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.
Design:
* This is a multicenter tissue procurement protocol with NCI as the coordinating center.
* For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
* For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
* Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.
* This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
* Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
* To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Eligibility:
-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.
Design:
* This is a multicenter tissue procurement protocol with NCI as the coordinating center.
* For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
* For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
* Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.
* This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
* Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tissue Collection for Studies of Lymph Cancer
NCT01676805
Hodgkin Disease
Lymphoma, Non-Hodgkin
Multiple Myeloma
+2 more
RECRUITING
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
NCT05600933
Solid Tumors
Hematologic Malignancy
Gastrointestinal Cancer
+5 more
ENROLLING_BY_INVITATION
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT01137643
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
+5 more
RECRUITING
Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers
NCT00580203
Head and Neck Cancers
COMPLETED
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
NCT00904514
Cancer
TERMINATED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Patients who are being evaluated and/or treated at the NIH Clinical Center and at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
To obtain specimens from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
To obtain specimens for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Eligibility:
Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and at participating sites.
Design:
This is a multicenter tissue procurement protocol with NCI as the coordinating center.
For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed on adult patients at the NIH Clinical Center for the sole purpose of obtaining tissue specimens or biological fluids. Tissues and biological fluids to be procured may include blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells (CTCs), hair follicles, bone marrow and bone marrow aspirate. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining specimens by minimally invasive measures, such as venipuncture.
This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways; and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
Patients who are being evaluated and/or treated at the NIH Clinical Center and at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
To obtain specimens from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
To obtain specimens for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Eligibility:
Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and at participating sites.
Design:
This is a multicenter tissue procurement protocol with NCI as the coordinating center.
For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed on adult patients at the NIH Clinical Center for the sole purpose of obtaining tissue specimens or biological fluids. Tissues and biological fluids to be procured may include blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells (CTCs), hair follicles, bone marrow and bone marrow aspirate. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining specimens by minimally invasive measures, such as venipuncture.
This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways; and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neoplasms
Lymphomas
Multiple Myeloma
Myelodysplastic Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1/Standard
Standard
Biopsy
Intervention Type
PROCEDURE
Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
2/Standard and Preclinical Models
Standard and Preclinical Models
No interventions assigned to this group
3/Preclinical Models
Preclinical Models
No interventions assigned to this group
4/Preclinical Models, Pediatric
Preclinical Models, Pediatric
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biopsy
Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients 18 years of age and older who are being evaluated and/or treated for cancer at the NIH Clinical Center or at participating sites:
* Who have a newly diagnosed malignancy for which they have not yet received treatment, or
* Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:
* radiographic evidence of tumor growth and/or new metastases, or
* CBC w/differential and/or flow cytometry, or
* documented evidence by the treating physician of signs/symptoms of clinical disease progression, or
* Who are currently undergoing treatment and for whom disease response has not yet been assessed,
---In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.
* Patients with ongoing partial response (PR) or stable disease (SD) are eligible.
* For solid tumor diagnoses, confirmation of viable malignancy and/or \<90% tumor necrosis, fibrosis, or hemorrhage per the final pathology must be reported to the coordinating site for patients enrolled with ongoing PR or SD at the time of specimen collection.
* For hematologic malignancies, confirmation of viable malignancy must be reported to the coordinating site per the final flow cytometry report.
* Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.
At the NIH Clinical Center ONLY:
* At the PIs discretion, specimens may be collected from patients 18 years of age and older prior to the development of an invasive cancer, who are being evaluated and/or treated for a confirmed familial cancer syndrome such as but not limited to Hereditary Breast and Ovarian Cancer (HBOC), Hereditary Non-polyposis Colorectal Cancer Syndrome or Hereditary Diffuse Gastric Cancer (HDGC) syndrome.
* Specimens, including blood only, can be collected from patients 18 years of age and older who are being evaluated and/or treated for a hematologic malignancy, including Myelodysplastic Syndrome (MDS) and/or MDS Myeloproliferative Neoplasm (MDS-MPN), that meet all other adult eligibility criteria.
* Due to the different characteristics of hematologic malignancies versus solid tumor malignancies, including methodology for assessment of disease response, residual disease, and progression, evaluation of these factors for determination of protocol eligibility should be made utilizing established standards such as hematopathology, flow cytometry, immunohistochemical analysis, etc.
* Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected.
* Ability and willingness to assent to participation, utilizing an explanation that is understandable/age appropriate, as well as receiving parental permission.
At the NIH Clinical Center ONLY
-At the PI s discretion, clinically indicated tissue collections may occur from patients with pediatric tumors that are generally benign but are known to undergo malignant transformation, e.g., neurofibromatosis, osteochondromas, pheochromocytoma, etc.
* Who have a newly diagnosed malignancy for which they have not yet received treatment, or
* Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:
* radiographic evidence of tumor growth and/or new metastases, or
* CBC w/differential and/or flow cytometry, or
* documented evidence by the treating physician of signs/symptoms of clinical disease progression, or
* Who are currently undergoing treatment and for whom disease response has not yet been assessed,
---In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.
* Patients with ongoing partial response (PR) or stable disease (SD) are eligible.
* For solid tumor diagnoses, confirmation of viable malignancy and/or \<90% tumor necrosis, fibrosis, or hemorrhage per the final pathology must be reported to the coordinating site for patients enrolled with ongoing PR or SD at the time of specimen collection.
* For hematologic malignancies, confirmation of viable malignancy must be reported to the coordinating site per the final flow cytometry report.
* Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.
At the NIH Clinical Center ONLY:
* At the PIs discretion, specimens may be collected from patients 18 years of age and older prior to the development of an invasive cancer, who are being evaluated and/or treated for a confirmed familial cancer syndrome such as but not limited to Hereditary Breast and Ovarian Cancer (HBOC), Hereditary Non-polyposis Colorectal Cancer Syndrome or Hereditary Diffuse Gastric Cancer (HDGC) syndrome.
* Specimens, including blood only, can be collected from patients 18 years of age and older who are being evaluated and/or treated for a hematologic malignancy, including Myelodysplastic Syndrome (MDS) and/or MDS Myeloproliferative Neoplasm (MDS-MPN), that meet all other adult eligibility criteria.
* Due to the different characteristics of hematologic malignancies versus solid tumor malignancies, including methodology for assessment of disease response, residual disease, and progression, evaluation of these factors for determination of protocol eligibility should be made utilizing established standards such as hematopathology, flow cytometry, immunohistochemical analysis, etc.
* Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected.
* Ability and willingness to assent to participation, utilizing an explanation that is understandable/age appropriate, as well as receiving parental permission.
At the NIH Clinical Center ONLY
-At the PI s discretion, clinically indicated tissue collections may occur from patients with pediatric tumors that are generally benign but are known to undergo malignant transformation, e.g., neurofibromatosis, osteochondromas, pheochromocytoma, etc.
Exclusion Criteria
* Patients with cancer-like syndromes and/or blood disorders such as but not limited to systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS).
* Patients with invasive fungal infections.
* Patients with active and/or uncontrolled infections or who are still recovering from an infection:
* All antibiotics, antifungals, or antivirals prescribed for the treatment of an infection should be completed at least 1 week (7 days) prior to collection.
* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics.
* Patients receiving antibiotics, antifungals, or antivirals for prophylaxis are permissible.
* Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible.
* Note: Use of antibiotics for prophylaxis is not an exclusion.
* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
--Note: Patients that are anti-HAV IgG reactive only are not excluded
* Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response:
* Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
* Blood will not be collected from patients between doses within a single treatment cycle.
* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR).
* Patients with invasive fungal infections
* Patients with active and/or uncontrolled infections or who are still recovering from an infection:
* Actively febrile patients with uncertain etiology of febrile episode
* All antibiotics should be completed at least 1 week (7 days) prior to collection
* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
* Note: Use of antibiotics for prophylaxis is not an exclusion.
* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
--Note: Patients that are anti-HAV IgG reactive only are not excluded
* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.
* Blood only collections from patients with partial or stable disease response:
* Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
* Blood will not be collected from patients between doses within a single treatment cycle.
* Patients with invasive fungal infections.
* Patients with active and/or uncontrolled infections or who are still recovering from an infection:
* All antibiotics, antifungals, or antivirals prescribed for the treatment of an infection should be completed at least 1 week (7 days) prior to collection.
* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics.
* Patients receiving antibiotics, antifungals, or antivirals for prophylaxis are permissible.
* Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible.
* Note: Use of antibiotics for prophylaxis is not an exclusion.
* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
--Note: Patients that are anti-HAV IgG reactive only are not excluded
* Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response:
* Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
* Blood will not be collected from patients between doses within a single treatment cycle.
* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR).
* Patients with invasive fungal infections
* Patients with active and/or uncontrolled infections or who are still recovering from an infection:
* Actively febrile patients with uncertain etiology of febrile episode
* All antibiotics should be completed at least 1 week (7 days) prior to collection
* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
* Note: Use of antibiotics for prophylaxis is not an exclusion.
* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
--Note: Patients that are anti-HAV IgG reactive only are not excluded
* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.
* Blood only collections from patients with partial or stable disease response:
* Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
* Blood will not be collected from patients between doses within a single treatment cycle.
Minimum Eligible Age
2 Months
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James H Doroshow, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Davis
Sacramento, California, United States
Site Status
COMPLETED
University of Colorado, Denver
Aurora, Colorado, United States
Site Status
COMPLETED
Emory University
Atlanta, Georgia, United States
Site Status
RECRUITING
Indiana University - Purdue
Indianapolis, Indiana, United States
Site Status
RECRUITING
University of Iowa
Iowa City, Iowa, United States
Site Status
RECRUITING
Johns Hopkins University
Baltimore, Maryland, United States
Site Status
RECRUITING
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
RECRUITING
University of Michigan Ann Arbor
Ann Arbor, Michigan, United States
Site Status
COMPLETED
Washington University - St. Louis
St Louis, Missouri, United States
Site Status
RECRUITING
Roswell Park Cancer Institute
Buffalo, New York, United States
Site Status
RECRUITING
Ohio State University
Columbus, Ohio, United States
Site Status
RECRUITING
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Site Status
RECRUITING
Medical University of South Carolina
Charleston, South Carolina, United States
Site Status
COMPLETED
University of Utah
Salt Lake City, Utah, United States
Site Status
COMPLETED
University of Virginia, Charlottesville
Charlottesville, Virginia, United States
Site Status
COMPLETED
Fred Hutchinson
Seattle, Washington, United States
Site Status
RECRUITING
Princess Margaret Hospital Cancer Centre
Toronto, , Canada
Site Status
COMPLETED
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Role: primary
800-411-1222 ext. TTY dial 711
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2006-C-0213.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-C-0213
Identifier Type: -
Identifier Source: secondary_id
060213
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
RECRUITING
Collecting Solid Tumor Tissue to Identify New Treatments
NCT01658917
COMPLETED
Collection of Tissue Blocks or Slides From Patients With Cancer
NCT02810405
COMPLETED
Collection of Blood, Bone Marrow, Tumor or Tissue Samples
NCT00043615
COMPLETED
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
NCT00900484
COMPLETED
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
NCT00071045
RECRUITING
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer
NCT00898300
COMPLETED
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
NCT00897767
COMPLETED
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
NCT00006518
RECRUITING
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
NCT00899275
COMPLETED
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT01915225
RECRUITING
Tissue Acquisition for Molecular Diagnostics
NCT00001580
COMPLETED
Rapid Autopsy and Procurement of Cancer Tissue
NCT01851395
RECRUITING
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT00026884
RECRUITING
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
NCT00898638
RECRUITING
Collection of Blood From Patients With Cancer
NCT00034216
RECRUITING
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
NCT01000753
COMPLETED
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
COMPLETED
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
NCT02682667
RECRUITING
Sample Collection and Tracking for the Developmental Therapeutics Clinic
NCT03269578
RECRUITING
Biology Studies of Hematologic Cancers
NCT00923442
ENROLLING_BY_INVITATION
Biospecimen Procurement for Head and Neck Disorders
NCT03429036
RECRUITING
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT01109394
RECRUITING
Collecting and Storing Blood Samples From Patients With Cancer
NCT00900120
WITHDRAWN